Turning the Spotlight on Lipids in Non-Apoptotic ... - ACS Publications

Reviews Cite This: ACS Chem. Biol. 2018, 13, 506−515

Turning the Spotlight on Lipids in Non-Apoptotic Cell Death Laura R. Parisi,† Lauren M. Morrow,† Michelle B. Visser,‡ and G. Ekin Atilla-Gokcumen*,† †

Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260, United States Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, New York 14260, United States

‡

ABSTRACT: Although apoptosis has long dominated the spotlight, studies in the past two decades have expanded the repertoire of programmed cell death (PCD). Several forms of non-apoptotic regulated cell death have been identified, with important links to organismal homeostasis and different disease pathologies. Necroptosis, ferroptosis, pyroptosis, and NETosis are the major forms of PCD that have attracted attention. Clear biochemical distinctions differentiate these forms of non-apoptotic PCD at the protein and membrane levels. For instance, pore formation at the plasma membrane is a hallmark of necroptosis and pyroptosis; however, different proteins facilitate pore formation in these processes. Here, we will highlight the role of lipids in different forms of non-apoptotic PCD. In particular, we discuss how lipids can trigger or facilitate the membrane-related changes that result in cell death. We also highlight the use of small molecules in elucidating the mechanisms of non-apoptotic PCD and the potential of lipid biosynthetic pathways to perturb these processes for therapeutic applications as a future avenue of research.

P

also recently been recognized as important signaling molecules and key regulators of processes such as cell division,4,5 senescence,6,7 and cell death.8−10 The mammalian lipidome consists of thousands of unique species, deriving its chemical diversity from different core structures, headgroups, and acyl chains (which can vary in length and number and position of double bonds). These structural differences give rise to unique physiochemical properties for each lipid species, affecting their cellular localization, their interactions within the cell, and the physical properties of the membrane in which they are present.11,12 Despite recent advancements in tools and techniques for studying lipids at the molecular level, the functions of individual lipids species in many cellular processes remain largely unknown. In the context of cell death, membrane-related morphological changes raise many questions. How does the cell utilize lipids during cell death? Are lipid species linked to specific signaling pathways? Are lipids involved in triggering cell death, or do they execute cell death by facilitating membrane-related changes? In this review, we will discuss the involvement of lipids in different forms of nonapoptotic PCD. We focus in particular on necroptosis, ferroptosis, and pyroptosis, which are of broad interest as they occur in multiple cell types and disease models. These forms of PCD involve specific membrane-related changes, and the roles of lipids in these processes have been the subject of previous reviews.13,14 Here we provide an updated overview of

rogrammed cell death (PCD) is essential for maintaining cellular homeostasis and can be activated by various pathological and physiological states. Imbalance between cell proliferation and PCD has been linked to many diseases, including cancer, neurodegenerative disorders, autoimmune diseases, and viral infections.1 Given the involvement of cell death in different diseases, understanding how these processes are triggered and facilitated by different biomolecules is of great therapeutic interest. The most widely recognized form of PCD is apoptosis. Apoptosis was initially characterized in 1972 by some of its distinct morphological features: cell shrinkage, nuclear and cytoplasmic condensation, and formation of apoptotic bodies.2 For many years, apoptosis was considered the only form of PCD, while necrosis was considered “accidental” death.3 However, accumulating evidence in recent years has revealed the existence of many different forms of nonapoptotic PCD, including necroptosis, ferroptosis, pyroptosis, NETosis, autosis, entosis, and parthanatos. Among these, necroptosis, ferroptosis, and pyroptosis are currently the best characterized. Distinct biochemical machineries regulate these different forms of PCD, each of which involves unique membrane-related changes. In the case of apoptosis, these changes include membrane blebbing and translocation of phosphatidylserine from the inner leaflet to the outer leaflet of the plasma membrane. In contrast, loss of plasma membrane integrity occurs during necroptosis, pyroptosis, and NETosis. Because of the loss of plasma membrane integrity, nonapoptotic PCD can cause inflammation at the organismal level.3 Lipids are essential biomolecules that are well recognized for their structural roles in cellular membranes. However, they have © 2018 American Chemical Society

Received: December 19, 2017 Accepted: January 26, 2018 Published: January 27, 2018 506

DOI: 10.1021/acschembio.7b01082 ACS Chem. Biol. 2018, 13, 506−515

Reviews

ACS Chemical Biology

Figure 1. Small molecules used to elucidate the molecular mechanisms of non-apoptotic programmed cell death. (A) Necrostatin-1, Nec-1s, and necrosulfonamide all inhibit necroptosis through the inhibition of key protein mediators. Necrostatin-1 and its more potent analogue, Nec-1s, inhibit RIP1, while necrosulfonamide inhibits MLKL oligomerization. (B) Erastin and RSL3 have been instrumental in identifying key mediators of the ferroptosis pathway, including GPXs. Ferrostatin-1, an inhibitor of ferroptosis, highlighted the importance of lipid peroxidation during this process. (C) The small molecule 7DG was discovered to inhibit pyroptosis through binding to PKR, which helped elucidate the role of PKR in inflammasome assembly and caspase-1 activation.

Figure 2. Mechanisms of non-apoptotic programmed cell deaths. Necroptosis is a form of regulated necrosis characterized by cellular swelling, plasma membrane permeabilization, and release of intracellular contents. It can be initiated upon death receptor activation in the absence of caspase8 activity, which leads to the activation of RIP1 and RIP3. Active RIP3 phosphorylates MLKL. MLKL oligomers translocate to the plasma membrane, where they interact with membrane lipids, including PIPs. These interactions result in the permeabilization of the plasma membrane. Ferroptosis is an iron-dependent form of cell death in which oxidative stress and lipid peroxidation have crucial roles. It can be induced when GPX4 activity is impaired. This results in the oxidation of PUFAs or PUFA-containing phospholipids (synthesized by ACSL4 and LPCAT3) and the formation of lipid peroxides. Pyroptosis is an inflammatory, caspase-1-dependent cell death that is characterized by the loss of plasma membrane integrity and the release of proinflammatory molecules. The process is initiated when certain pattern recognition receptors are activated and assemble inflammasomes, which often contain the adaptor protein ASC. The inflammasomes activate caspase-1, which proteolytically matures proinflammatory cytokines and cleaves GSDMD to release its N-terminus (GSDMD-NT). GSDMD-NT oligomerizes and translocates to the plasma membrane, where it interacts with membrane lipids and forms pores. NETosis is a form of programmed cell death in which activated neutrophils release threadlike chromatin structures covered with antimicrobial proteins, which bind and kill pathogens. At the onset of NETosis, activated neutrophils become flattened; then chromatin decondensation occurs, and nuclei expand and lose their lobular shape. Nuclear and granular membranes disintegrate, and decondensed chromatin mixes with granular and cytoplasmic proteins, forming NETs. Finally, the plasma membrane ruptures, and NETs are released. 507


Reviews


tidylserine.27 Furthermore, small molecule inhibitors of PIKfyve and phosphatase and tensin homologue (PTEN) reduce the rate of cell death due to TNF-induced necroptosis,26 affirming the functional role of these lipids during necroptosis and suggesting that perturbation of PIPs can modulate necroptotic activity. High-resolution structural characterization of MLKL oligomerization and membrane association suggested that PIP binding occurs in a multistep process.28 The first step involves oligomerization facilitating a low-affinity binding to the plasma membrane. At the membrane, the N-terminal helix bundle domain of MLKL undergoes structural arrangement, which exposes binding sites on the domain that have a high affinity for PIPs. Experiments in micelles that aimed to investigate the interaction of the N-terminal helix bundle domain with different PIPs suggested a binding preference for PI(4,5)P2 in the presence of PI and PI(4)P.28 In addition to PIPs, other lipids are beginning to be recognized to have potential roles during necroptosis. Our laboratory recently conducted the first untargeted metabolomics study to investigate changes in the lipidome during necroptosis.9 We found that very long-chain fatty acids (VLCFAs) were among the most significant changes in the lipidome during necroptosis. Fatty acid synthase (FASN) and elongation of very long-chain fatty acid proteins 1 and 7 (ELOVL1 and ELOVL7, respectively) were upregulated during necroptosis, suggesting that fatty acid biosynthesis and elongation are responsible for the accumulation of VLCFAs observed during necroptosis. Knockdown of FASN9 or ELOVL1/7 (unpublished data) via shRNA also prevented necroptotic cell death. We also demonstrated that a small molecule inhibitor of FASN, cerulenin, prevented the accumulation of VLCFAs, cell death, and membrane permeabilization due to necroptosis.9 Together, these findings firmly indicate that VLCFAs play a functional role during necroptosis. On the basis of our observations, changes at the lipid level occur downstream from activation of the death pathway. As such, we think these lipids do not induce necroptosis but rather may be involved in the membrane-related changes that facilitate cell death by altering lipid and/or protein organization in the plasma membrane, either by themselves or potentially through incorporation into more complex lipids such as PIPs. Ceramides have also been linked to necroptosis, although the nature of their involvement is still an open question. Both we9 and others29,30 have found that ceramides accumulate during necroptosis. However, the mechanism resulting in the accumulation of ceramides or other up- or downstream sphingolipids during necroptosis is yet to be determined. Some studies have suggested that cell death is mediated by increased ceramide levels as a result of sphingomyelinase activity.29,31 Another recent study, on the other hand, has suggested sphingosine and sphingosine 1-phosphate (for a review of the roles of these signaling lipids, see ref 32) as the mediators of cell death using a ceramidase knockout model.33 It is possible that multiple pathways could be activated in different cellular contexts. Necroptosis has been linked to a number of different disease states. For example, it has been shown that many different bacteria induce cell death in macrophages via pore-forming toxins that induce necroptosis, contributing to bacterial pneumonia.34 Upregulation of proteins involved in the necroptotic machinery such as RIP3 has been associated with inflammatory diseases such as ulcerative colitis,35 while

the roles of lipids during necroptosis, ferroptosis, and pyroptosis and also discuss potential roles of specific lipids during NETosis, which is less well characterized but may involve drastic remodeling of cellular membranes. We will also highlight the use of small molecules to examine the molecular mechanisms of non-apoptotic death programs and how they have helped to elucidate the roles of lipids in these processes.

■

NECROPTOSIS Discovery and Molecular Mechanisms. Necroptosis is a form of regulated cell death that results in hallmark features of necrosis, including cellular swelling, loss of plasma membrane integrity, and the release of intracellular contents. Traditionally, necrotic cell death was considered to be unregulated, and apoptosis was considered the sole form of programmed cell death. However, in the late 1980s, observations that death receptor activation could result in necrotic cell death led researchers to speculate that a different category of cell death might exist.15 Several studies in the late 1990s showed that inhibition of caspases promoted necrotic cell death (reviewed in ref 16). In 2000, Holler et al.17 demonstrated that receptor interacting protein 1 (RIP1), which had been previously been linked to death receptor signaling, was necessary for caspaseindependent necrotic cell death induced by death receptor ligands. In 2005, Degterev et al.18 identified a small molecule inhibitor of RIP1-dependent, caspase-independent necrotic cell death called necrostatin-1 (Figure 1) and coined the term necroptosis to describe this pathway. Later studies elucidated other key regulatory proteins involved in necroptosis, including receptor interacting protein 3 (RIP3) (for a review of these discoveries, see ref 16) and mixed lineage kinase domain-like protein (MLKL), which was identified via immunoprecipitation studies with a small molecule inhibitor, necrosulfonamide19 (Figure 1). A number of different agents induce necroptosis;20 however, the molecular mechanisms have perhaps been most welldefined for tumor necrosis factor (TNF)-induced necroptosis. Briefly, when death receptor TNFR1 is activated and prosurvival nuclear factor-κB activation is suppressed, a cytosolic complex containing RIP1, RIP3, and caspase-8 (among other proteins) can form (reviewed in ref 21). Under these conditions, caspase-8 activity governs whether a cell will undergo apoptosis or necroptosis. If caspase-8 is active, it cleaves RIP122 and RIP3,23 preventing their activation, and apoptosis proceeds. If caspase-8 is inactive, however, a complex called the necrosome containing RIP1, RIP3, and MLKL forms.19 Within this complex, RIP3 phosphorylates MLKL, which promotes MLKL oligomerization and translocation to the plasma membrane (Figure 2), a step that is essential for the execution of necroptosis.24 Recently published evidence suggests that MLKL forms pores or cation channels at the plasma membrane that disrupt osmotic balance, leading to the eventual rupture of the plasma membrane.25 Emerging Roles of PIPs and Other Lipids. Given the important membrane-related changes that occur during necroptosis, it comes as no surprise that lipids have been shown to play key roles in this process. MLKL has been shown to interact with a number of different phosphatidylinositol phosphates (PIPs)26,27 and also with cardiolipin27 (diphosphatidylglycerolipids that are primarily located in the inner mitochondrial membrane in mammalian cells). MLKL induces leakage of liposomes containing PIPs or cardiolipin, but not that of liposomes containing phosphatidylinositol or phospha508


Reviews

ACS Chemical Biology suppression of RIP336 and MLKL37 has been associated with cancer. Treatment with RIP1 inhibitor necrostatin-1 or its more selective analogue, Nec-1s (Figure 1), has ameliorated a number of different pathologies, including allograft rejection,38 ischemia/reperfusion injuries,18 and neurodegenerative diseases.39 However, we note the pharmacokinetic and pharmacodynamic limitations of necrostatin-140 and suggest that future studies using compounds with higher selectivity will be key to establishing the role of necroptosis in these pathologies. Given the importance of lipids during necroptosis, it will be crucial to evaluate how perturbing lipid biosynthesis modulates necroptosis in disease models. Our data, for instance, suggest that perturbing VLCFA biosynthesis may delay necroptotic cell death.9 Currently, no selective inhibitors of individual ELOVLs exist, but their development could lead to a better understanding of the roles of individual lipids during necroptosis and other processes and provide potential therapeutic applications.

glutathione-dependent peroxidases (GPXs),47 which can reduce organic peroxides such as lipid peroxides to hydroxides.49 The same study showed that RSL3 directly binds and inhibits the peroxidase activity of GPX4, knockdown of GPX4 strongly sensitized cells to RSL3-induced ferroptosis, and overexpression of GPX4 conferred resistance to cell death, finally providing a unified underlying mechanism to begin to understand how these molecules induce ferroptosis (Figure 2). Fundamental Role of Lipid Peroxidation. It seemed likely from quite early on that lipids may be involved during ferroptosis, and evidence that lipid peroxidation is integral to this process continues to accumulate. Proteins that mediate ferroptotic cell death are directly involved in lipid-related pathways. Inactivation of GPX4 is central to erastin- and RSL3induced ferroptosis. GPX4 utilizes glutathione to reduce lipid peroxides, a function that is important for preventing the propagation of oxidative damage to other lipids and biomolecules.49 Gpx4 knockout in mice is embryonic lethal,50 and inducible knockout of Gpx4 causes ferroptosis accompanied by increased levels of lipid hydroperoxides.51 In addition to GPX4, aldo-keto reductase AKR1C family enzymes, which may also play a role in the detoxification of products of lipid peroxidation,52 may be involved in ferroptosis. Erastin/RSL3 resistant clonal cell lines selected by maintained large doses of erastin showed >500-fold increases in the level of expression of two AKR1C family genes.46 Lipoxygenases,53 on the other hand, promote ferroptosis. Knockdown of arachidonic lipoxygenases (ALOXs) has been shown to reduce sensitivity to erastin-induced ferroptosis.54 However, the context in which lipoxygenases participate in ferroptosis is not entirely clear and may be dependent on glutathione levels54 or other potential mediators such as phosphatidylethanolamine binding protein 1, which has been shown to interact with 15-lipoxygenases under certain conditions and may promote oxidation of phosphatidylethanolamines.55 In addition to proteins involved in lipid peroxidation, lipid biosynthetic enzymes play key roles in ferroptosis. Genetic screens revealed that the loss of function of acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3), confers a survival advantage during ferroptosis.56 ACSL4 preferentially activates PUFAs57 for synthesis of complex lipids (for example, phospholipids and glycerolipids), which are more susceptible to lipid peroxidation than monounsaturated or saturated fatty acids. Acsl4 knockout cells are highly resistant to ferroptosis,58,59 and Lpcat3 knockdown also confers resistance to ferroptosis, although to a lesser extent.58 These findings suggest that PUFA-containing phospholipids play a key role in ferroptotic cell death. Indeed, several lipidomic studies have shown that ferroptosis is accompanied by changes in phospholipid composition. Inducible knockout of Gpx4 caused ferroptotic cell death and increased levels of hydroperoxy-fatty acids, -phosphatidylcholines, -phosphatidylethanolamines, and -cardiolipins as well as increased levels of lysophosphatidylcholines and lysophosphatidylethanolamines in mouse kidneys.51 A lipidomic analysis of cells treated with an erastin analogue found depletion of PUFAcontaining phosphatidylcholines and an increase in the level of lysophosphatidylcholine among the most significant changes in the lipidome.54 In another recent study, oxidized phospholipid species were detected among the wild type, Gpx4 knockout, and Acsl4 knockout mouse embryonic fibroblasts during RSL3induced ferroptosis. Among these species, the authors proposed

■

FERROPTOSIS Discovery and Molecular Mechanisms. Ferroptosis is an iron-dependent form of cell death in which glutathione, oxidative stress, and lipid peroxidation play crucial roles. As early as the 1970s, it was appreciated that dysregulation of intracellular iron can cause cell death. While studies in the subsequent years showed that iron chelators and a lipophilic antioxidant (vitamin E) could prevent cell death due to glutathione depletion (reviewed in ref 41), it was not until very recently that ferroptosis was recognized as a unique form of cell death. The identification and characterization of ferroptosis were pioneered by the Stockwell laboratory. These investigations stemmed from key studies in the early to mid-2000s that aimed to screen for small molecules with genotypeselective toxicity toward oncogenic RAS.42,43 Among the compounds they identified, two novel small molecules, erastin and RSL3 (Figure 1), induced non-apoptotic cell death. Studies that aimed to investigate the mechanism of action of these compounds showed that erastin- and RSL3-induced cell death was not caspase-dependent, nor did erastin-induced cell death result in typical changes in morphology characteristic of apoptosis or necrosis.43−45 Intriguingly, however, iron chelators and vitamin E prevented erastin- and RSL3-induced cell death,43 suggesting a crucial role for reactive oxygen species (ROS) in this process, which was named ferroptosis by Dixon et al. in 2012.45 Dixon et al. also showed that ferrostatin-1 (Figure 1), a small molecule identified to inhibit erastininduced ferroptosis, prevented accumulation of cytosolic ROS and lipid peroxidation.45 Initial studies that aimed to determine the target of erastin highlighted mitochondrial voltage-dependent anion channel proteins (VDACs),44 which were suggested as potential mediators of ROS during ferroptosis. Indeed, shRNA knockdown of VDAC3 can prevent the loss of cell viability due to erastin-induced ferroptosis, albeit only to a certain extent and only in specific cell lines.44,45 However, another mechanism of action was soon identified. Small molecule-based modulatory profiling led to the discovery that erastin is an inhibitor of system xc−,45,46 a cell surface cystine-glutamate antiporter. Metabolomics revealed that erastin treatment results in a depletion of glutathione,47 presumably because of the limited availability of cysteine as a result of system xc− inhibition because the rate-limiting step of glutathione biosynthesis is the condensation of cysteine with glutamate48 (Figure 2). Erastin treatment was then shown to decrease the activity of 509


Reviews


some phenotypic features of pyroptosis overlap with those of other cell deaths, clear biochemical distinctions established pyroptosis as an independent death pathway. Studies with Salmonella typhimurium revealed the inflammatory nature and caspase-1 dependence of pyroptosis,71 distinguishing it from non-inflammatory apoptotic pathways. DNA damage occurs during both apoptosis and pyroptosis, but pyroptotic cells maintain nuclear integrity and display a DNA fragmentation pattern different from that of apoptotic cells.71 Similar to necroptotic cells, pyroptotic cells exhibit plasma membrane permeabilization and release proinflammatory molecules, in contrast to the non-inflammatory removal of apoptotic bodies during apoptosis.3,69,71 These distinct features lead Cookson et al. to aptly name the pathway pyroptosis in 2001, derived from the Greek root pyro-, meaning “fire” in reference to its inflammatory nature.72 Following initial characterizations, other recently described phenotypic changes include membrane blebbing prior to plasma membrane rupture and the release of fragments of the cell body, named pyroptotic bodies.73 Because of its inflammatory nature, pyroptosis has been observed in many disease and injury states.69 At the cellular level, pyroptosis is initiated upon activation of pattern recognition receptors (PRRs) [reviewed in refs 68 and 69 (see Figure 2)]. Cells use a variety of these receptors, including membrane-bound C type lectin and Toll-like receptors, as well as intracellular receptors such as NOD-like receptors (NLRs) and DNA sensing absent in melanoma 2 (AIM2) during pyroptosis. When these receptors detect signals generated either by the host cell in response to stress or tissue injury or by invading pathogens, they initiate signaling cascades (reviewed in ref 74). Some PRRs, including AIM2, the protein pyrin, and the Nod-like receptors Nlrp3, Nlrp1b, and Nlrc4, assemble inflammasomes (Figure 2).68,74 These multiprotein complexes recruit and activate caspase-1 through adaptor proteins such as ASC (apoptosis-associated specklike protein containing a caspase activation and recruitment domain).74 Hung and coworkers elucidated the mechanism of inflammasome assembly during pyroptosis by using the small molecule 7DG (Figure 1), which suppressed cell death. They identified protein kinase R as the target of 7DG, placing protein kinase R as a central molecule in inflammasome assembly and caspase-1 activation during pyroptosis.75 While dozens of protein targets exist for caspases during apoptosis, evidence indicates that only a few caspase targets are necessary for the progression of pyroptosis. One key protein target in the pyroptotic pathway is Gasdermin D (GSDMD).76 Activated caspase-1 facilitates pyroptosis through cleavage of GSDMD to generate an N-terminal cleavage product (GSDMD-NT), which oligomerizes and translocates to the plasma membrane, where it forms pores.68,77,78 In addition, activated caspase-1 causes the maturation of pro-IL-1β to its cleaved active form. IL-1β is subsequently released from the cell along with other proinflammatory mediators through the GSDMD-NT-mediated plasma membrane pores.79 The transmembrane flux of molecules, including ions and cytokines, through the plasma membrane pores ultimately results in lysis of the cell.73 Although plasma membrane permeabilization is characteristic of both pyroptosis and necroptosis, there are differences in how the permeabilization facilitates cell death. These differences can be linked to properties of the pores generated by GSDMD-NT and MLKL. Studies have suggested that MLKL forms selective cation channels that generate osmotic imbalance, resulting in

phosphatidylethanolamines containing arachidonic acid (C20:4) or adrenic acid (C22:4) as key drivers of ferroptosis because their levels correlated with the degree of cell death.58 The precise chemical structures of different lipids influence their susceptibility to oxidation, and it is clear that structure has a functional impact on the roles of lipids during ferroptosis. A recent study that investigated the role of lipoxygenases in ferroptosis showed the modulatory effect of a number of different lipids on RSL3 treatment. It was found that oleic acid (a monounsaturated fatty acid) strongly suppressed ferroptotic cell death, while arachidonic acid and linoleic acid (polyunsaturated fatty acids) sensitized cells to ferroptotic cell death.54 The authors also showed that labeling linoleic acid with deuterium in the bis-allylic position, which slows the rate of peroxide formation, prevented generation of lipid peroxides and ferroptotic cell death.54 Another study that suggested the key involvement of ACSL4 in ferroptosis showed that addition of ω-6 fatty acids generally sensitized Acsl4 knockout cells to ferroptosis, while ω-3 fatty acids had little to no effect,59 with the exception of docosahexaenoic acid. It is clear that lipid peroxidation plays a central role in ferroptosis; however, several major questions remain. The precise mechanism(s) by which lipid peroxidation results in ferroptotic cell death still needs to be elucidated. Although lipid peroxidation can significantly alter membrane fluidity and permeability, it is possible that products of lipid peroxide degradation such as malondialdehyde and 4-hydroxynonenal react with other biomolecules, including protein and DNA,60 exerting toxic effects. Similarly, despite iron dependence being a defining characteristic, the role of iron during ferroptosis is also still not thoroughly understood. Ferroptosis can be inhibited by a number of iron chelators and has been shown to be modulated by the availability of transferrin−iron complexes.61 However, it is unclear whether ferroptosis proceeds via production of hydroxyl radicals through Fe2+ or iron-dependent lipid-processing enzymes.62 Ferrostatin-1 (Figure 1), which was shown to prevent cell death in Huntington’s disease and other disease models, has been shown to prevent depletion of PUFAs due to erastin treatment, without affecting glutathione levels.63 Besides ferrostatin-1, a number of classes of antioxidants can inhibit ferroptosis with a similar or better potency that correlates with their ability to prevent oxidation of liposomes.64 It seems clear that ferrostatin-1 prevents ferroptosis by preventing peroxidation of PUFAs and/or other PUFAcontaining lipids45,63 because of its function as a lipophilic antioxidant.65 Thus far, ferroptosis has been linked to pathological processes, including ischemia/reperfusion injuries and certain neurodegenerative diseases, and a few studies have suggested a potential role in tumor suppression.66,67 While apoptosis has well-established roles in development and tumor suppression, and other forms of regulated cell death (i.e., necroptosis, pyroptosis, and NETosis) have links to defense against pathogens, a beneficial role of ferroptosis at the organismal level has yet to be elucidated.

■

PYROPTOSIS Discovery and Molecular Mechanisms. Pyroptosis is an inflammatory, caspase-1-dependent programmed cell death that primarily occurs in macrophages and neutrophils.68,69 Because of its caspase dependenceat the time, a hallmark of apoptosisinitial observations of pyroptotic death in infected macrophages were misidentified as apoptosis.69,70 Although 510


Reviews


extracellular environment that can bind and kill various bacteria, viruses, and fungi.86 NETs were first described in 2004, when researchers observed that neutrophils released networks of threadlike structures in response to certain stimuli.84 These structures contained histone-rich chromatin backbones decorated with antimicrobial granule proteins, which were able to bind and kill pathogens, including Gram-negative and -positive bacteria.84 Following initial characterizations, NET formation and release were proposed to be part of a novel cell death program (later named NETosis87) because of distinct characteristics, including a lack of DNA fragmentation and disintegration of the nuclear membrane.85 Emerging evidence indicates that NETosis may progress through distinct signaling pathways that are stimulus-dependent.88 Classically, NETosis has been described as an NADPH oxidase (Nox)-dependent death program that results in NET formation and release facilitated by compromised cellular membranes. To date, the mechanistic details of pathways involved in NETosis have not been well characterized89 but seem to involve protein kinase C and Raf/MEK/ERK pathways.90,91 NETosis involves intriguing morphological changes that have been captured by live cell imaging and transmission electron microscopy studies.85 At the onset of NETosis, activated neutrophils initially become flattened and form intracellular vacuoles. Subsequently, nuclei expand and lose their characteristic lobular shape, and chromatin decondensation occurs. Granular materials become distributed throughout the cytoplasm, and the nuclear membrane disintegrates, allowing decondensed chromatin to interact with cytoplasmic and granular materials, thus allowing NETs to form. Eventually, the plasma membrane ruptures, allowing the NETs to be released from the cell body.85 In addition to Nox-dependent NETosis, other pathways involving NET formation and release have also been described. Calcium-selective bacterial ionophores, which bind and transport cations across cell membranes, have been shown to induce release of NET-like structures in a Nox-independent manner.88,92 Furthermore, recent reports indicate that certain stimuli can induce “vital NETosis”, which involves release of either nuclear or mitochondrial DNA in the absence of cell lysis (reviewed in ref 93). Although NETosis has been considered a beneficial antimicrobial mechanism, dysregulated NETosis may also lead to the development and exacerbation of inflammatory diseases.86 It is therefore important to fill the gaps in knowledge concerning how different biomolecules, including lipids, facilitate the morphological changes that lead to the formation of extracellular traps. Roles of Lipids in NETosis. Membranes play important roles during NETosis at multiple stages. First, the nuclear envelope disintegrates to allow chromatin to interact with granular proteins and cytoplasmic materials to form NETs. Second, the plasma membrane ruptures, releasing the NETs, along with other intracellular material, to the extracellular matrix. Given that lipids can modulate the biophysical properties of membranes,12 it is reasonable to expect that specific lipids and changes in lipid composition may contribute to the membrane-related changes during NETosis. Recent studies have shown that NET formation is sensitive to the cellular levels of an important membrane lipid, cholesterol. Treatment with statins94 and methyl-β-cyclodextrin95 to reduce cholesterol levels in neutrophils resulted in increased rates of

the necroptotic hallmarks of cellular swelling and plasma membrane rupture.25 In contrast, pores formed by GSDMDNT lack ion selectivity.73 As a result, a change in osmotic pressure should have less effect during pyroptosis than during necroptosis.73 Roles of Lipids in Pyroptosis. Recent studies have suggested that lipids play roles in pyroptosis, both as triggers and as facilitators of the membrane-related phenotypes involved in this process. A specific oxysterol80 and fatty acid81 have been reported to activate pyroptotic cell death. 25-Hydroxycholesterol activates P2X7, an ion channel, and caspase-1, resulting in the release of inflammatory cytokines via pyroptosis.80,82 Pillon et al.81 have shown that palmitate, a saturated fatty acid, increases the activity of inflammatory caspases and induces membrane permeabilization and the release of inflammatory cytokines, indicating pyroptotic activity. In contrast, unsaturated fatty acids palmitoleate and oleate did not elicit inflammatory responses or toxicity.81 In addition to their roles in activating the pyroptotic pathway, lipids are also likely involved in facilitating the membrane-related changes occurring during pyroptosis. Because interaction with membrane lipids might affect membrane localization and pore formation, Liu et al.77 and Ding et al.78 investigated potential interactions between GSDMD-NT and certain membrane lipids. Consistent with previous findings that GSDMD-NT facilitates membrane permeabilization during pyroptosis,76 full length GSDMD, mutant GSDMD-NT,77 and GSDMD-CT do not interact with membrane lipids, while GSDMD-NT shows lipid binding.77,78 Studies in liposomes showed that GSDMD-NT could bind to PIPs, cardiolipin, phosphatidic acid (PA), and phosphatidylserine (PS) species,77,78 but not to phosphatidylethanolamine or phosphatidylcholine.77 Interestingly, each of the lipids shown to interact with GSDMD-NT is net anionic under physiological conditions, which likely contributes to the binding interactions. Additionally, while PIPs, PA, and PS are components of the inner leaflet of the plasma membrane in mammalian cells, cardiolipins are major components of the inner mitochondrial membrane in mammalian cells12 and are also present in bacterial membranes.83 As such, these findings indicate that GSDMD-NT binds to the inner mammalian plasma membrane and potentially to mitochondrial or bacterial plasma membranes.77 However, these interactions remain to be demonstrated in vivo. Intriguing questions regarding the molecular interactions between GSDMD-NT oligomers and membrane lipids also remain to be elucidated, including how the electrostatic properties of the lipid headgroup, surface properties of the protein, and overall lipid composition of membranes mediate these interactions. Additionally, further studies are needed to identify any lipid metabolic enzymes that are required for the progression of pyroptosis, similar to the chemical and genetic screens that helped to elucidate the crucial involvement of lipid peroxidation during ferroptosis.

■

NETOSIS Discovery and Characterization. A neutrophil is a type of immune cell that can bind, engulf, and kill invading pathogens.84 As terminally differentiated cells, neutrophils have a short life span but have been shown to extend their antimicrobial activity through the release of extracellular traps.85 Neutrophil extracellular traps (NETs) are potent antimicrobial structures released by neutrophils to the 511


Reviews


and have been particularly instrumental in elucidating different forms of non-apoptotic PCD. For instance, chemical screens identifying erastin and RSL3 led to the identification of ferroptosis as a unique form of cell death. Similarly, the identification of RIP1 inhibitor necrostatin-1 helped to solidify necroptosis as a distinct, regulated form of non-apoptotic cell death.18 In the case of pyroptosis, small molecule 7DG, which was also identified via a chemical screen, helped to elucidate some aspects of inflammasome assembly and caspase-1 activation.75 Given the important roles of lipids in these different forms of cell death, small molecules targeting lipid biosynthesis have begun to emerge as important tools for understanding downstream events in these pathways, and as potential therapeutic agents. Small molecules targeting fatty acid9 and PIP26 biosynthesis have been shown to modulate necroptosis, while small molecule inhibitors of ACSL4 have been shown to protect against ferroptosis.59 Different forms of PCD are implicated in diverse pathologies ranging from neurodegenerative diseases to pathogen infection, inflammatory conditions, and autoimmune diseases. Efforts to understand the contributions of different forms of PCD to disease are growing in parallel with the awareness that lipids play important roles in these processes. Enzymes related to lipid biosynthesis and processing have evolved to process and could therefore be targeted by small molecules. However, because our understanding of the roles of individual lipids is limited, these enzymes have not yet been prioritized for drug discovery. As our understating of the involvement and regulation of different lipids in PCDs advances, we expect that the development of lipid-centered therapeutic strategies will emerge as an exciting avenue of research.

NET formation and release. Cholesterol and other lipids are thought to be important signaling platforms in various cellular events, including host−pathogen interactions.96 On this basis, it is plausible that cholesterol, in combination with other lipids, could influence the physical properties of membranes (i.e., overall membrane fluidity) or promote specific signaling events via membrane domains in activated neutrophils and facilitate their rupture. Another lipid that may potentially regulate NETosis is Hepoxilin A3. Hepoxilin A3 is a proinflammatory, oxidized eicosanoid secreted by epithelial cells in response to bacterial infection that recruits neutrophils to the site of infection. Neutrophils exposed to Hepoxilin A3 or a synthetic analogue have been shown to release DNA to the extracellular environment in a dose- and time-dependent manner.97 However, we are only just beginning to understand the roles of lipids in NETosis. The signaling processes and downstream events driving NET formation and release have been only partially characterized. As such, there is certainly a need for further mechanistic understanding of NETosis, including the roles of lipids in this process. In this regard, we expect that future studies that aim to investigate changes in the lipidome or localization of specific lipids during different stages of NETosis may provide critical insights.

■

CONCLUSIONS Over the past decade, it has become clear that there are many pathways by which our cells can die, each of which involves unique membrane-related phenotypes where lipids play important roles. In some cases, specific lipids can cause the activation of these pathways. In other cases, however, lipids seem to function downstream of the activation of protein machinery, where distinct changes in lipid composition and/or protein−lipid interactions have critical functions in the execution of cell death. The time is ripe to ask ourselves: can we harness the functions of lipids to perturb cellular processes, including cell death? Studies that explore lipid-centered therapeutic strategies have indeed demonstrated the potential to modulate cell death in vivo. For example, nanoliposomes containing C6-ceramide (which induce MLKL-dependent necrotic cell death in vitro) were shown to suppress metastasis in a mouse xenograft model.98 However, a great deal of work remains to understand the precise contributions of different forms of cell death in vivo. For instance, although apoptosis is often considered the primary form of cell death induced by most chemotherapeutic agents, is it the sole mechanism of tumor cell death? Could other forms of cell death provide an alternative strategy for treating apoptosis resistant tumors? Certain chemotherapeutic agents have been shown to induce necroptosis.20 Furthermore, it has recently been shown that secondary necrosis (late-stage necrosis that occurs in apoptotic cells) may in some cases be a regulated process that is executed by caspase-3-dependent cleavage to release the N-terminal fragment of gasdermin superfamily protein DFNA5/GSDME.99 The underlying similarity of highly regulated pore formation events among necroptosis, pyroptosis, and potentially secondary necrosis is intriguing. Further investigations into the differences between these events are warranted, particularly with regard to how interactions with lipids enable these proteins to form pores in cellular membranes. Small molecule-based approaches have been fundamental in understanding the mechanisms of different cellular processes

■

AUTHOR INFORMATION

Corresponding Author

*E-mail: ekinatil@buffalo.edu. ORCID

Laura R. Parisi: 0000-0003-4868-1426 G. Ekin Atilla-Gokcumen: 0000-0002-7132-3873 Notes

The authors declare no competing financial interest.

■

512

KEYWORDS necroptosis: a highly regulated form of necrotic cell death characterized by cellular swelling, plasma membrane rupture, and release of intracellular contents PIPs: phosphatidylinositol phosphates, a class of phospholipids that can be phosphorylated at multiple positions at the inositol headgroup; these lipids recruit proteins to the plasma membrane during necroptosis PTEN: phosphatase and tensin homologue that dephosphorylates proteins and the third position of PI(3,4,5)P3 PIKfyve: phosphoinositide kinase that preferentially phosphorylates the fifth position of PIs and PI(3)Ps ferroptosis: an iron-dependent form of programmed cell death that is characterized by the accumulation of lipid peroxides; key protein regulators are involved in lipid biosynthesis and peroxidation pyroptosis: an inflammatory, caspase-1-dependent form of cell death characterized by DNA fragmentation, plasma membrane permeabilization, and release of proinflammatory cytokines DOI: 10.1021/acschembio.7b01082 ACS Chem. Biol. 2018, 13, 506−515

Reviews


(2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112−119. (19) Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X., and Wang, X. (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213−227. (20) Su, Z., Yang, Z., Xie, L., DeWitt, J. P., and Chen, Y. (2016) Cancer therapy in the necroptosis era. Cell Death Differ. 23, 748−756. (21) Dondelinger, Y., Darding, M., Bertrand, M. J. M., and Walczak, H. (2016) Poly-ubiquitination in TNFR1-mediated necroptosis. Cell. Mol. Life Sci. 73, 2165−2176. (22) Lin, Y., Devin, A., Rodriguez, Y., and Liu, Z.-g. (1999) Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 13, 2514−2526. (23) Feng, S., Yang, Y., Mei, Y., Ma, L., Zhu, D.-e., Hoti, N., Castanares, M., and Wu, M. (2007) Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell. Signalling 19, 2056−2067. (24) Cai, Z., Jitkaew, S., Zhao, J., Chiang, H.-C., Choksi, S., Liu, J., Ward, Y., Wu, L.-G., and Liu, Z.-G. (2014) Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat. Cell Biol. 16, 55−65. (25) Ros, U., Peñ a-Blanco, A., Hänggi, K., Kunzendorf, U., Krautwald, S., Wong, W. W.-L., and García-Sáez, A. J. (2017) Necroptosis execution is mediated by plasma membrane nanopores independent of calcium. Cell Rep. 19, 175−187. (26) Dondelinger, Y., Declercq, W., Montessuit, S., Roelandt, R., Goncalves, A., Bruggeman, I., Hulpiau, P., Weber, K., Sehon, C. A., Marquis, R. W., Bertin, J., Gough, P. J., Savvides, S., Martinou, J. C., Bertrand, M. J., and Vandenabeele, P. (2014) MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 7, 971−981. (27) Wang, H., Sun, L., Su, L., Rizo, J., Liu, L., Wang, L.-F., Wang, F.S., and Wang, X. (2014) Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54, 133−146. (28) Quarato, G., Guy, C. S., Grace, C. R., Llambi, F., Nourse, A., Rodriguez, D. A., Wakefield, R., Frase, S., Moldoveanu, T., and Green, D. R. (2016) Sequential engagement of distinct MLKL phosphatidylinositol−binding sites executes necroptosis. Mol. Cell 61, 589−601. (29) Voigt, S., Philipp, S., Davarnia, P., Winoto-Morbach, S., Röder, C., Arenz, C., Trauzold, A., Kabelitz, D., Schütze, S., Kalthoff, H., and Adam, D. (2014) TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. BMC Cancer 14, 74. (30) Sawai, H., Ogiso, H., and Okazaki, T. (2015) Differential changes in sphingolipids between TNF-induced necroptosis and apoptosis in U937 cells and necroptosis-resistant sublines. Leuk. Res. 39, 964−970. (31) Thon, L., Mohlig, H., Mathieu, S., Lange, A., Bulanova, E., Winoto-Morbach, S., Schutze, S., Bulfone-Paus, S., and Adam, D. (2005) Ceramide mediates caspase-independent programmed cell death. FASEB J. 19, 1945−1956. (32) Hannun, Y. A., and Obeid, L. M. (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139−150. (33) Sundaram, K., Mather, A. R., Marimuthu, S., Shah, P. P., Snider, A. J., Obeid, L. M., Hannun, Y. A., Beverly, L. J., and Siskind, L. J (2016) Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death. Biochem. J. 473, 743−755. (34) Gonzalez-Juarbe, N., Gilley, R. P., Hinojosa, C. A., Bradley, K. M., Kamei, A., Gao, G., Dube, P. H., Bergman, M. A., and Orihuela, C. J. (2015) Pore-forming toxins induce macrophage necroptosis during acute bacterial pneumonia. PLoS Pathog. 11, e1005337. (35) Pierdomenico, M., Negroni, A., Stronati, L., Vitali, R., Prete, E., Bertin, J., Gough, P. J., Aloi, M., and Cucchiara, S. (2014) Necroptosis is active in children with inflammatory bowel disease and contributes to heighten intestinal inflammation. Am. J. Gastroenterol. 109, 279− 287.

inflammasome: multiprotein complexes that mediate the activation of proinflammatory caspases in response to pathogen- and host-derived “danger signals”; inflammasomes activate caspase-1 to induce pyroptosis NETosis: a form of cell death in which neutrophils form and release antimicrobial extracellular traps; NETosis is characterized by disintegration of nuclear and granule membranes, chromatin condensation, and release of neutrophil extracellular traps into the extracellular environment ceramidase: enzyme that catalyzes the hydrolysis of ceramides into fatty acid and sphingosine species sphingomyelinase: enzyme that catalyzes the hydrolysis of sphingomyelins into ceramides

■

REFERENCES

(1) Thompson, C. B. (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456−1462. (2) Kerr, J. F. R., Wyllie, A. H., and Currie, A. R. (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239−257. (3) Zhang, Y., Chen, X., Gueydan, C., and Han, J. (2018) Plasma membrane changes during programmed cell deaths. Cell Res. 28, 9. (4) Atilla-Gokcumen, G. E., Muro, E., Relat-Goberna, J., Sasse, S., Bedigian, A., Coughlin, M. L., Garcia-Manyes, S., and Eggert, U. S. (2014) Dividing cells regulate their lipid composition and localization. Cell 156, 428−439. (5) Cauvin, C., and Echard, A. (2015) Phosphoinositides: Lipids with informative heads and mastermind functions in cell division. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 1851, 832−843. (6) Lizardo, D. Y., Lin, Y. L., Gokcumen, O., and Atilla-Gokcumen, G. E. (2017) Regulation of lipids is central to replicative senescence. Mol. BioSyst. 13, 498−509. (7) Flor, A. C., Wolfgeher, D., Wu, D., and Kron, S. J. (2017) A signature of enhanced lipid metabolism, lipid peroxidation and aldehyde stress in therapy-induced senescence,. Cell Death Discovery 3, 17075. (8) Li, N., Lizardo, D. Y., and Atilla-Gokcumen, G. E. (2016) Specific triacylglycerols accumulate via increased lipogenesis during 5-FUinduced apoptosis. ACS Chem. Biol. 11, 2583−2587. (9) Parisi, L. R., Li, N., and Atilla-Gokcumen, G. E. (2017) Very long chain fatty acids are functionally involved in necroptosis. Cell Chem. Biol. 24, 1445−1454. (10) Ogretmen, B. (2017) Sphingolipid metabolism in cancer signalling and therapy. Nat. Rev. Cancer 18, 33. (11) Lizardo, D. Y., Parisi, L. R., Li, N., and Atilla-Gokcumen, G. E. (2018) Noncanonical roles of lipids in different cellular fates. Biochemistry 57, 22. (12) van Meer, G., Voelker, D. R., and Feigenson, G. W. (2008) Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112−124. (13) Magtanong, L., Ko, P. J., and Dixon, S. J. (2016) Emerging roles for lipids in non-apoptotic cell death. Cell Death Differ. 23, 1099−1109. (14) Agmon, E., and Stockwell, B. R. (2017) Lipid homeostasis and regulated cell death. Curr. Opin. Chem. Biol. 39, 83−89. (15) Laster, S. M., Wood, J. G., and Gooding, L. R. (1988) Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J. Immunol. 141, 2629−2634. (16) Weinlich, R., Oberst, A., Beere, H. M., and Green, D. R. (2017) Necroptosis in development, inflammation and disease. Nat. Rev. Mol. Cell Biol. 18, 127−136. (17) Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J. L., Schneider, P., Seed, B., and Tschopp, J. (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1, 489−495. (18) Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A., and Yuan, J. 513


Reviews

ACS Chemical Biology (36) Koo, G. B., Morgan, M. J., Lee, D. G., Kim, W. J., Yoon, J. H., Koo, J. S., Kim, S. I., Kim, S. J., Son, M. K., Hong, S. S., Levy, J. M., Pollyea, D. A., Jordan, C. T., Yan, P., Frankhouser, D., Nicolet, D., Maharry, K., Marcucci, G., Choi, K. S., Cho, H., Thorburn, A., and Kim, Y. S. (2015) Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 25, 707−725. (37) He, L., Peng, K., Liu, Y., Xiong, J., and Zhu, F.-f. (2013) Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. OncoTargets Ther. 6, 1539−1543. (38) Lau, A., Wang, S., Jiang, J., Haig, A., Pavlosky, A., Linkermann, A., Zhang, Z. X., and Jevnikar, A. M. (2013) RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am. J. Transplant. 13, 2805−2818. (39) Ofengeim, D., Ito, Y., Najafov, A., Zhang, Y., Shan, B., DeWitt, J. P., Ye, J., Zhang, X., Chang, A., Vakifahmetoglu-Norberg, H., Geng, J., Py, B., Zhou, W., Amin, P., Lima, J. B., Qi, C., Yu, Q., Trapp, B., and Yuan, J. (2015) Activation of necroptosis in multiple sclerosis. Cell Rep. 10, 1836−1849. (40) Degterev, A., Maki, J. L., and Yuan, J. (2013) Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ. 20, 366. (41) Cao, J. Y., and Dixon, S. J. (2016) Mechanisms of ferroptosis. Cell. Mol. Life Sci. 73, 2195−2209. (42) Dolma, S., Lessnick, S. L., Hahn, W. C., and Stockwell, B. R. (2003) Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285−296. (43) Yang, W. S., and Stockwell, B. R. (2008) Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15, 234−245. (44) Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., Smukste, I., Peltier, J. M., Boniface, J. J., Smith, R., Lessnick, S. L., Sahasrabudhe, S., and Stockwell, B. R. (2007) RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 865− 868. (45) Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., III, and Stockwell, B. R (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060− 1072. (46) Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., and Stockwell, B. R. (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523. (47) Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., Brown, L. M., Girotti, A. W., Cornish, V. W., Schreiber, S. L., and Stockwell, B. R. (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317−331. (48) Lu, S. C. (2013) Glutathione synthesis. Biochim. Biophys. Acta, Gen. Subj. 1830, 3143−3153. (49) Brigelius-Flohé, R., and Maiorino, M. (2013) Glutathione peroxidases. Biochim. Biophys. Acta, Gen. Subj. 1830, 3289−3303. (50) Yant, L. J., Ran, Q., Rao, L., Van Remmen, H., Shibatani, T., Belter, J. G., Motta, L., Richardson, A., and Prolla, T. A. (2003) The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radical Biol. Med. 34, 496−502. (51) Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., Basavarajappa, D., Radmark, O., Kobayashi, S., Seibt, T., Beck, H., Neff, F., Esposito, I., Wanke, R., Forster, H., Yefremova, O., Heinrichmeyer, M., Bornkamm, G. W., Geissler, E. K., Thomas, S. B., Stockwell, B. R., O’Donnell, V. B., Kagan, V. E., Schick, J. A., and

Conrad, M. (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180−1191. (52) Burczynski, M. E., Sridhar, G. R., Palackal, N. T., and Penning, T. M. (2001) The reactive oxygen species−and Michael acceptorinducible human aldo-keto reductase AKR1C1 reduces the alpha,betaunsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J. Biol. Chem. 276, 2890−2897. (53) Kuhn, H., Banthiya, S., and van Leyen, K. (2015) Mammalian lipoxygenases and their biological relevance. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 1851, 308−330. (54) Yang, W. S., Kim, K. J., Gaschler, M. M., Patel, M., Shchepinov, M. S., and Stockwell, B. R. (2016) Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci. U. S. A. 113, E4966. (55) Wenzel, S. E., Tyurina, Y. Y., Zhao, J., St. Croix, C. M., Dar, H. H., Mao, G., Tyurin, V. A., Anthonymuthu, T. S., Kapralov, A. A., Amoscato, A. A., Mikulska-Ruminska, K., Shrivastava, I. H., Kenny, E. M., Yang, Q., Rosenbaum, J. C., Sparvero, L. J., Emlet, D. R., Wen, X., Minami, Y., Qu, F., Watkins, S. C., Holman, T. R., VanDemark, A. P., Kellum, J. A., Bahar, I., Bayir, H., and Kagan, V. E. (2017) PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 171, 628−641. (56) Dixon, S. J., Winter, G. E., Musavi, L. S., Lee, E. D., Snijder, B., Rebsamen, M., Superti-Furga, G., and Stockwell, B. R. (2015) Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem. Biol. 10, 1604−1609. (57) Kang, M.-J., Fujino, T., Sasano, H., Minekura, H., Yabuki, N., Nagura, H., Iijima, H., and Yamamoto, T. T. (1997) A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc. Natl. Acad. Sci. U. S. A. 94, 2880−2884. (58) Kagan, V. E., Mao, G., Qu, F., Angeli, J. P., Doll, S., Croix, C. S., Dar, H. H., Liu, B., Tyurin, V. A., Ritov, V. B., Kapralov, A. A., Amoscato, A. A., Jiang, J., Anthonymuthu, T., Mohammadyani, D., Yang, Q., Proneth, B., Klein-Seetharaman, J., Watkins, S., Bahar, I., Greenberger, J., Mallampalli, R. K., Stockwell, B. R., Tyurina, Y. Y., Conrad, M., and Bayir, H. (2017) Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81−90. (59) Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., Prokisch, H., Trumbach, D., Mao, G., Qu, F., Bayir, H., Fullekrug, J., Scheel, C. H., Wurst, W., Schick, J. A., Kagan, V. E., Angeli, J. P. F., and Conrad, M. (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91−98. (60) Gaschler, M. M., and Stockwell, B. R. (2017) Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun. 482, 419−425. (61) Gao, M., Monian, P., Quadri, N., Ramasamy, R., and Jiang, X. (2015) Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298−308. (62) Doll, S., and Conrad, M. (2017) Iron and ferroptosis: a still illdefined liaison. IUBMB Life 69, 423−434. (63) Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., Lo, D. C., Weinberg, J. M., Linkermann, A., and Stockwell, B. R. (2014) Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136, 4551−4556. (64) Shah, R., Margison, K., and Pratt, D. A. (2017) The potency of diarylamine radical-trapping antioxidants as inhibitors of ferroptosis underscores the role of autoxidation in the mechanism of cell death. ACS Chem. Biol. 12, 2538−2545. (65) Zilka, O., Shah, R., Li, B., Friedmann Angeli, J. P., Griesser, M., Conrad, M., and Pratt, D. A. (2017) On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent. Sci. 3, 232−243. (66) Jiang, L., Kon, N., Li, T., Wang, S. J., Su, T., Hibshoosh, H., Baer, R., and Gu, W. (2015) Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57−62. (67) Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascon, S., Hatzios, S. K., Kagan, V. 514


Reviews

ACS Chemical Biology E., Noel, K., Jiang, X., Linkermann, A., Murphy, M. E., Overholtzer, M., Oyagi, A., Pagnussat, G. C., Park, J., Ran, Q., Rosenfeld, C. S., Salnikow, K., Tang, D., Torti, F. M., Torti, S. V., Toyokuni, S., Woerpel, K. A., and Zhang, D. D. (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273−285. (68) Vande Walle, L., and Lamkanfi, M. (2016) Pyroptosis. Curr. Biol. 26, R568−R572. (69) Cookson, B. T., Bergsbaken, T., and Fink, S. L. (2009) Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7, 99−109. (70) Chen, Y. J., Smith, M. R., Thirumalai, K., and Zychlinsky, A. (1996) A bacterial invasin induces macrophage apoptosis by binding directly to ICE. EMBO J. 15, 3853−3860. (71) Brennan, M. A., and Cookson, B. T. (2000) Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol. Microbiol. 38, 31−40. (72) Cookson, B. T., and Brennan, M. A. (2001) Pro-inflammatory programmed cell death. Trends Microbiol. 9, 113−114. (73) Chen, X., He, W.-t., Hu, L., Li, J., Fang, Y., Wang, X., Xu, X., Wang, Z., Huang, K., and Han, J. (2016) Pyroptosis is driven by nonselective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 26, 1007−1020. (74) Schroder, K., and Tschopp, J. (2010) The inflammasomes. Cell 140, 821−832. (75) Hett, E. C., Slater, L. H., Mark, K. G., Kawate, T., Monks, B. G., Stutz, A., Latz, E., and Hung, D. T. (2013) Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nat. Chem. Biol. 9, 398−405. (76) Shi, J. J., Zhao, Y., Wang, K., Shi, X. Y., Wang, Y., Huang, H. W., Zhuang, Y. H., Cai, T., Wang, F. C., and Shao, F. (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660−665. (77) Liu, X., Zhang, Z. B., Ruan, J. B., Pan, Y. D., Magupalli, V. G., Wu, H., and Lieberman, J. (2016) Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153− 153. (78) Ding, J. J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J. J., Sun, H. Z., Wang, D. C., and Shao, F. (2016) Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111− 111. (79) He, W. T., Wan, H. Q., Hu, L. C., Chen, P. D., Wang, X., Huang, Z., Yang, Z. H., Zhong, C. Q., and Han, J. H. (2015) Gasdermin D is an executor of pyroptosis and required for interleukin1 beta secretion. Cell Res. 25, 1285−1298. (80) Olivier, E., Dutot, M., Regazzetti, A., Laprévote, O., and Rat, P. (2017) 25-hydroxycholesterol induces both P2 × 7-dependent pyroptosis and caspase-dependent apoptosis in human skin model: new insights into degenerative pathways. Chem. Phys. Lipids 207, 171− 178. (81) Pillon, N. J., Chan, K. L., Zhang, S., Mejdani, M., Jacobson, M. R., Ducos, A., Bilan, P. J., Niu, W., and Klip, A. (2016) Saturated fatty acids activate caspase-4/5 in human monocytes, triggering IL-1beta and IL-18 release. Am. J. Physiol. 311, E825. (82) Divirgilio, F. (2007) Liaisons dangereuses: P2 × 7 and the inflammasome. Trends Pharmacol. Sci. 28, 465−472. (83) Schlame, M. (2008) Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J. Lipid Res. 49, 1607−1620. (84) Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., Weinrauch, Y., and Zychlinsky, A. (2004) Neutrophil extracellular traps kill bacteria. Science 303, 1532− 1535. (85) Fuchs, T. A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V., Weinrauch, Y., Brinkmann, V., and Zychlinsky, A. (2007) Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176, 231−241. (86) Delgado-Rizo, V., Martínez-Guzmán, M., Iñiguez-Gutierrez, L., García-Orozco, A., Alvarado-Navarro, A., and Fafutis-Morris, M.

(2017) Neutrophil extracellular traps and its implications in inflammation: an overview. Front. Immunol. 8, 1−20. (87) Steinberg, B. E., and Grinstein, S. (2007) Unconventional roles of the NADPH oxidase: signaling, ion homeostasis, and cell death. Sci. Signaling 2007, pe11. (88) Kenny, E. F., Herzig, A., Kruger, R., Muth, A., Mondal, S., Thompson, P. R., Brinkmann, V., Bernuth, H. V., and Zychlinsky, A. (2017) Diverse stimuli engage different neutrophil extracellular trap pathways. eLife 6, e24437. (89) Konig, M. F., and Andrade, F. (2016) A critical reappraisal of neutrophil extracellular traps and NETosis mimics based on differential requirements for protein citrullination,. Front. Immunol. 7, 461. (90) Hakkim, A., Martinez, N. E., Fuchs, T. A., Hess, S., Prinz, H., Zychlinsky, A., and Waldmann, H. (2011) Activation of the Raf-MEKERK pathway is required for neutrophil extracellular trap formation. Nat. Chem. Biol. 7, 75−77. (91) Gray, R. D., Lucas, C. D., MacKellar, A., Li, F., Hiersemenzel, K., Haslett, C., Davidson, D. J., and Rossi, A. G. (2013) Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps. J. Inflammation (London, U. K.) 10, 12−12. (92) Parker, H., Dragunow, M., Hampton, M. B., Kettle, A. J., and Winterbourn, C. C. (2012) Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation differ depending on the stimulus. J. Leukocyte Biol. 92, 841−849. (93) Yipp, B. G., and Kubes, P. (2013) NETosis: how vital is it? Blood 122, 2784−2794. (94) Chow, O. A., von Köckritz-Blickwede, M., Bright, A. T., Hensler, M. E., Zinkernagel, A. S., Cogen, A. L., Gallo, R. L., Monestier, M., Wang, Y., Glass, C. K., and Nizet, V. (2010) Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8, 445−454. (95) Neumann, A., Brogden, G., Jerjomiceva, N., Brodesser, S., Naim, H. Y., and von Kockritz-Blickwede, M. (2014) Lipid alterations in human blood-derived neutrophils lead to formation of neutrophil extracellular traps. Eur. J. Cell Biol. 93, 347−354. (96) Riethmüller, J., Riehle, A., Grassmé, H., and Gulbins, E. (2006) Membrane rafts in host−pathogen interactions. Biochim. Biophys. Acta, Biomembr. 1758, 2139−2147. (97) Douda, D. N., Grasemann, H., Pace-Asciak, C., and Palaniyar, N. (2015) A lipid mediator hepoxilin A3 is a natural inducer of neutrophil extracellular traps in human neutrophils. Mediators Inflammation 2015, 1−7. (98) Zhang, X., Kitatani, K., Toyoshima, M., Ishibashi, M., Usui, T., Minato, J., Egiz, M., Shigeta, S., Fox, T., Deering, T., Kester, M., and Yaegashi, N. (2018) Ceramide nanoliposomes as a MLKL-dependent, necroptosis-inducing, chemotherapeutic reagent in ovarian cancer. Mol. Cancer Ther. 17, 50. (99) Rogers, C., Fernandes-Alnemri, T., Mayes, L., Alnemri, D., Cingolani, G., and Alnemri, E. S. (2017) Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat. Commun. 8, 14128.

515


Turning the Spotlight on Lipids in Non-Apoptotic ... - ACS Publications

Recommend Documents